Evidence map›Paper›PMID 37362552›Full record

ArticleSchizophrenia bulletin open2023

Negative Symptom Trajectories in Individuals at Clinical High Risk for Psychosis: Differences Based on Deficit Syndrome, Persistence, and Transition Status.

Tanya Tran, Michael J Spilka, Ian M Raugh, Gregory P Strauss, Carrie E Bearden, Kristin S Cadenhead, Tyrone D Cannon, Barbara A Cornblatt, Matcheri Keshavan, Daniel H Mathalon and 8 more

Open access · goldAbstract read
In one paragraph

Article in Schizophrenia bulletin open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 2 countries.

Tanya TranDepartment of Psychology, Queen's University, Kingston, ON, Canada.ORCID https://orcid.org/0000-0002-6303-8394
Michael J SpilkaDepartment of Psychology, University of Georgia, Athens, GA, USA.
Ian M RaughDepartment of Psychology, University of Georgia, Athens, GA, USA.ORCID https://orcid.org/0000-0003-4981-2395
Gregory P StraussDepartment of Psychology, University of Georgia, Athens, GA, USA.
Carrie E BeardenDepartment of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-8516-923X
Kristin S CadenheadDepartment of Psychiatry, UCSD, San Diego, CA, USA.ORCID https://orcid.org/0000-0002-5952-4605
Tyrone D CannonDepartment of Psychology, Yale University, New Haven, CT, USA.
Barbara A CornblattDepartment of Psychiatry, Zucker Hillside Hospital, Long Island, NY, USA.
Matcheri KeshavanDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, MA, USA.
Daniel H MathalonDepartment of Psychiatry, UCSF, and SFVA Medical Center, San Francisco, CA, USA.
Thomas H McGlashanDepartment of Psychiatry, Yale University, New Haven, CT, USA.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.
Larry J SeidmanDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, MA, USA.
William S StoneDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, MA, USA.ORCID https://orcid.org/0000-0003-2932-7288
Ming T TsuangDepartment of Psychiatry, UCSD, San Diego, CA, USA.
Elaine F WalkerDepartment of Psychology, Emory University, Atlanta, GA, USA.ORCID https://orcid.org/0000-0002-9798-8101
Scott W WoodsDepartment of Psychiatry, Yale University, New Haven, CT, USA.
Jean M AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Beth Israel Deaconess Medical Center · USUniversity of Georgia · USYale University · USUniversity of California San Diego · USEmory University · USNeurobehavioral Systems · USQueen's University · CAUniversity of Calgary · CAUniversity of North Carolina at Chapel Hill · USZucker Hillside Hospital · US

Funding

4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
NIMH NIH HHS U01 MH081857
6 · The paper itself

Abstract

Background and Hypothesis: Negative symptom trajectory in clinical high risk (CHR) for psychosis is ill defined. This study aimed to better characterize longitudinal patterns of change in negative symptoms, moderators of change, and differences in trajectories according to clinical subgroups. We hypothesized that negative symptom course will be nonlinear in CHR. Clinical subgroups known to be more severe variants of psychotic illness-deficit syndrome (DS), persistent negative syndrome (PNS), and acute psychosis onset-were expected to show more severe baseline symptoms, slower rates of change, and less stable rates of symptom resolution. Study Design: Linear, curvilinear, and stepwise growth curve models, with and without moderators, were fitted to negative symptom ratings from the NAPLS-3 CHR dataset ( Study Results: Negative symptoms followed a downward curvilinear trend, with marked improvement 0-6 months that subsequently stabilized (6-24 months), particularly among those with lower IQ and functioning. Clinical subgroups had higher baseline ratings, but distinct symptom courses; DS vs non-DS: more rapid initial improvement, similar stability of improvements; PNS vs non-PNS: similar rates of initial improvement and stability; transition vs no transition: slower rate of initial improvement, with greater stability of this rate. Conclusions: Continuous, frequent monitoring of negative symptoms in CHR is justified by 2 important study implications: (1) The initial 6 months of CHR program enrollment may be a key window for improving negative symptoms as less improvement is likely afterwards, (2) Early identification of clinical subgroups may inform distinct negative symptom trajectories and treatment needs.

Indexed as

cognitionfunctioninggrowth curve analysissymptom course

Identifiers

PMID37362552
PMCPMC10287168
OpenAlexW4379185339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.